CPT1B，一种代谢分子，也是 CN-AML 的独立危险因素。

CPT1B, a metabolic molecule, is also an independent risk factor in CN-AML.

机构信息

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, China.

出版信息

Cancer Biomark. 2023;37(3):133-145. doi: 10.3233/CBM-210043.

DOI:10.3233/CBM-210043

PMID:36938722

Abstract

BACKGROUND

Fatty acid oxidation has been considered as an important energy source for tumorigenesis and development. Several studies have investigated the role of CPT1A, a kind of fatty acid oxidation rate-limiting enzyme, in AML. However, prognostic value and regulatory network of another subtype, CPT1B in AML remains elusive. This study aims to clarify the independent prognostic role of CPT1B in CN-AML based on clinical data and molecular level data (mRNA, miRNA and lncRNA).

OBJECTIVE

The aim of this study is to investigate the prognostic value of CPT1B in AML patients.

METHODS

First, we analyzed the CPT1B expression in AML cohort via the online database "GEPIA". Subsequently, miRNA-mRNA and ceRNA networks were constructed to help predict the role of CPT1B in AML. Several molecules which showed the prognostic value and metabolic function of CPT1B were identified. Finally, the expression of CPT1B in our own cohort of 324 CN-AML patients was analyzed to clarify the results.

RESULTS

It was found that CPT1B was markedly higher in AML patients compared to normal people and this upregulation was associated with the poor clinical outcome. Several molecules revealed the possible regulatory mechanism of CPT1B in AML.

CONCLUSION

CPT1B is a potential prognostic factor and a therapeutic target for AML treatment.

摘要

背景

脂肪酸氧化已被认为是肿瘤发生和发展的重要能量来源。已有几项研究探讨了脂肪酸氧化限速酶 CPT1A 在 AML 中的作用。然而，另一种亚型 CPT1B 在 AML 中的预后价值和调控网络仍不清楚。本研究旨在基于临床数据和分子水平数据（mRNA、miRNA 和 lncRNA），阐明 CPT1B 在 CN-AML 中的独立预后作用。

目的

本研究旨在探讨 CPT1B 在 AML 患者中的预后价值。

方法

首先，我们通过在线数据库“GEPIA”分析了 AML 队列中 CPT1B 的表达。随后，构建了 miRNA-mRNA 和 ceRNA 网络，以帮助预测 CPT1B 在 AML 中的作用。鉴定了一些具有 CPT1B 预后价值和代谢功能的分子。最后，分析了我们自己的 324 例 CN-AML 患者队列中 CPT1B 的表达，以验证结果。